Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.35 |
| ▸ | ABL1 | P00519 | 4/20 | 0.34 |
| ▸ | BCR | P11274 | 4/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479194 | 1.00 | RXRA (0.37) | RXRARXRBEGLN1ABL1BCR | |
| SCHEMBL4477906 | 0.81 | KDM4E (0.36) | RXRARXRBHDAC8TEK | |
| SCHEMBL4479657 | 0.81 | KDM4E (0.36) | RXRARXRBHDAC8TEK | |
| SCHEMBL4484461 | 0.77 | BRAF (0.40) | EGLN1ABL1BCRHPGDSALKBH2 | |
| SCHEMBL4478699 | 0.76 | EGLN1 (0.44) | EGLN1ABL1BCR | |
| SCHEMBL4479189 | 0.74 | ABL1 (0.42) | EGLN1ABL1BCR | |
| SCHEMBL4463276 | 0.74 | ABL1 (0.42) | EGLN1ABL1BCR | |
| SCHEMBL4463281 | 0.74 | ABL1 (0.42) | EGLN1ABL1BCR | |
| SCHEMBL4491870 | 0.73 | EGLN1 (0.35) | RXRARXRBEGLN1ABL1BCR | |
| SCHEMBL4486668 | 0.71 | XDH (0.40) | EGLN1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | claimed |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | claimed |
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL2 | RXRA 1673/4885RXRB 1643/4885EGLN1 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.